ReviewJournal of human hypertension2005
Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?
Review in Journal of human hypertension, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 50 citations in OpenAlex.
- Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2007Trial
- Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.Clinical drug investigation · 2007Trial
- Blood Pressure Variability in Hypertension: A Rehabilitation Perspective.Journal of cardiovascular development and disease · 2025Review
- Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model.The Journal of clinical investigation · 2021Article
- ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2021Review
- Effects of dual inhibition of renin-angiotensin-aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits.Internal and emergency medicine · 2020Review
- Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2011Review
- Comparing angiotensin II receptor blockers on benefits beyond blood pressure.Advances in therapy · 2010Review
- High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin.American journal of nephrology · 2009Article
- Renal resistive index and cardiovascular organ damage in a large population of hypertensive patients.Journal of human hypertension · 2007Article
- Multivariate risk assessment and risk score cards in hypertension.Vascular health and risk management · 2007Review
- Optimizing hypertension management in clinical practice.Journal of human hypertension · 2006Review
- Towards understanding the aetiology and pathophysiology of human hypertension: where are we now?Journal of human hypertension · 2006Article
- Non-lethal fetal toxicity of the angiotensin receptor blocker candesartan.Pediatric nephrology (Berlin, Germany) · 2006Article
- Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.PharmacoEconomics · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective treatment of hypertension is essential to reduce the risk of renal and cardiovascular (CV) morbidity. The risks associated with hypertension are modulated by the presence of other factors. This has prompted the quest for agents that have benefits beyond blood pressure (BP) lowering. The angiotensin II receptor blocker (ARB) class of antihypertensive agents represents an important addition to the therapeutic options for elevated BP. Their ability to control BP is equivalent to existing therapies and there is a considerable and mounting evidence-base for their ability to reduce hypertension-associated target organ damage and comorbidities. Studies show that ARBs have clinical benefits across the spectrum of disease severity. In particular, recent large studies have demonstrated that these benefits extend to patients with conditions predisposing to CV events, such as diabetes, left ventricular hypertrophy and microalbuminuria, and where risk factors coexist. Data from these studies suggest that the CV protective effects of ARBs are at least, in part, independent from the BP lowering action. In addition, ARBs are extremely well tolerated, and strong evidence suggests that compliance with therapy--a key factor in achieving adequate BP control--with ARBs is higher than with other antihypertensive agents. Furthermore, flexible dosing and good tolerability profile mean that, where necessary, ARBs can be combined with other classes of antihypertensive agents to achieve adequate BP control and reduce the risk of hypertension-associated morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.